Sections
| Title | Starting Page | Number of Pages |
|---|
| Table of Contents | 2 | 4 |
| List of Tables | 5 | 1 |
| List of Figures | 5 | 1 |
| Introduction | 6 | 1 |
| Global Markets Direct Report Coverage | 6 | 1 |
| Leukocyte Surface Antigen CD47 (Antigenic Surface Determinant Protein OA3 or Integrin Associated Protein or Protein MER6 or CD47) Overview | 7 | 1 |
| Therapeutics Development | 8 | 3 |
| Leukocyte Surface Antigen CD47 (Antigenic Surface Determinant Protein OA3 or Integrin Associated Protein or Protein MER6 or CD47) Products under Development by Stage of Development | 8 | 1 |
| Leukocyte Surface Antigen CD47 (Antigenic Surface Determinant Protein OA3 or Integrin Associated Protein or Protein MER6 or CD47) Products under Development by Therapy Area | 9 | 1 |
| Leukocyte Surface Antigen CD47 (Antigenic Surface Determinant Protein OA3 or Integrin Associated Protein or Protein MER6 or CD47) Products under Development by Indication | 10 | 1 |
| Leukocyte Surface Antigen CD47 (Antigenic Surface Determinant Protein OA3 or Integrin Associated Protein or Protein MER6 or CD47) Pipeline Products Glance | 11 | 1 |
| Early Stage Products | 11 | 1 |
| Leukocyte Surface Antigen CD47 (Antigenic Surface Determinant Protein OA3 or Integrin Associated Protein or Protein MER6 or CD47) Products under Development by Companies | 12 | 2 |
| Leukocyte Surface Antigen CD47 (Antigenic Surface Determinant Protein OA3 or Integrin Associated Protein or Protein MER6 or CD47) Products under Development by Universities/Institutes | 14 | 2 |
| Leukocyte Surface Antigen CD47 (Antigenic Surface Determinant Protein OA3 or Integrin Associated Protein or Protein MER6 or CD47) Therapeutics Assessment | 16 | 5 |
| Assessment by Monotherapy/Combination Products | 16 | 1 |
| Assessment by Mechanism of Action | 17 | 1 |
| Assessment by Route of Administration | 18 | 1 |
| Assessment by Molecule Type | 19 | 2 |
| Leukocyte Surface Antigen CD47 (Antigenic Surface Determinant Protein OA3 or Integrin Associated Protein or Protein MER6 or CD47) Companies Involved in Therapeutics Development | 21 | 3 |
| Aurigene Discovery Technologies Limited | 21 | 1 |
| Celgene Corporation | 22 | 1 |
| Trillium Therapeutics Inc. | 23 | 1 |
| Leukocyte Surface Antigen CD47 (Antigenic Surface Determinant Protein OA3 or Integrin Associated Protein or Protein MER6 or CD47) Drug Profiles | 24 | 13 |
| B-6H12 Drug Profile | 24 | 1 |
| CC-90002 Drug Profile | 25 | 1 |
| Monoclonal Antibody to Inhibit CD47 for Cardiovascular Disease and Kidney Transplantation Drug Profile | 26 | 2 |
| Monoclonal Antibody to Inhibit IAP for Diabetic Retinopathy Drug Profile | 28 | 1 |
| Peptide to Inhibit CD47 for Oncology Drug Profile | 29 | 1 |
| Recombinant Proteins to Inhibit CD47 for Oncology Drug Profile | 30 | 1 |
| Small Molecules to Inhibit CD47 for Oncology Drug Profile | 31 | 1 |
| TTI-508 Drug Profile | 32 | 1 |
| TTI-621 Drug Profile | 33 | 3 |
| TTI-622 Drug Profile | 36 | 1 |
| Leukocyte Surface Antigen CD47 (Antigenic Surface Determinant Protein OA3 or Integrin Associated Protein or Protein MER6 or CD47) Dormant Projects | 37 | 1 |
| Leukocyte Surface Antigen CD47 (Antigenic Surface Determinant Protein OA3 or Integrin Associated Protein or Protein MER6 or CD47) Featured News &Press Releases | 38 | 7 |
| Jun 07, 2016: Trillium Therapeutics Announces Presentation on TTI-621 Immune Checkpoint Inhibitor Targeting CD47 at European Hematology Association 21st Annual Congress | 38 | 1 |
| May 18, 2016: Trillium Therapeutics Announces Presentation on TTI-621 Immune Checkpoint Inhibitor Targeting CD47 at 2016 ASCO Annual Meeting | 38 | 1 |
| Apr 14, 2016: Trillium to Provide Update on CD47 Program at the 2016 American Association for Cancer Research Annual Meeting | 38 | 1 |
| Mar 10, 2016: Trillium Announces a $3.4 Million Government Co-Funded Translational Research Program | 39 | 1 |
| Feb 03, 2016: Trillium Therapeutics Doses First Patient With TTI-621, a Novel Immune Checkpoint Inhibitor Targeting CD47 | 40 | 1 |
| Dec 03, 2015: Trillium to Provide Update on CD47 Immune Checkpoint Inhibitor Program at the 2015 American Society of Hematology Annual Meeting | 40 | 1 |
| Sep 30, 2015: Trillium Therapeutics Provides Update on CD47 Program | 41 | 1 |
| Apr 16, 2015: Trillium To Provide Update On CD47 Program At The 2015 American Association For Cancer Research Annual Meeting | 41 | 1 |
| May 31, 2013: Engineered Molecules Boost Immune Attack On Cancer | 42 | 1 |
| Apr 04, 2012: Trillium Provides Update On Anti-CD47 Cancer Program | 43 | 1 |
| Dec 02, 2010: Trillium To Present Preliminary Results From Cancer Stem Cell Program At ASH Annual Meeting | 44 | 1 |
| Appendix | 45 | 2 |
| Methodology | 45 | 1 |
| Coverage | 45 | 1 |
| Secondary Research | 45 | 1 |
| Primary Research | 45 | 1 |
| Expert Panel Validation | 45 | 1 |
| Contact Us | 45 | 1 |
| Disclaimer | 46 | 1 |
